The clinical relevance of pathologic subtypes in metastatic lung adenocarcinoma

Journal of Thoracic Oncology

Volumn 9, Issue 5, 2014, Pages 654-663

  Clay, Timothy D ^a,b   Do, Hongdo ^c,d   Sundararajan, Vijaya ^e   Moore, Melissa M ^a,b   Conron, Matthew ^a,b   Wright, Gavin M ^a,b   McLachlan, Sue Anne ^a,b   Dobrovic, Alexander ^c,d   Russell, Prudence A ^a,d  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

EGFR; Histopathology; KRAS; Metastatic lung adenocarcinoma

Indexed keywords

AFATINIB; CARBOPLATIN; ERLOTINIB; FORMALDEHYDE; GEFITINIB; GEMCITABINE; MUCIN; PARAFFIN; PLATINUM DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ACINAR CELL; ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CHEMORADIOTHERAPY; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DNA SEQUENCE; EFGR GENE; FEMALE; GENE; GENE MUTATION; HAZARD RATIO; HIGH RESOLUTION MELTING ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KRAS GENE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOLECULAR PATHOLOGY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PLEURA METASTASIS; PREVALENCE; PRIORITY JOURNAL; SMOKING; TUMOR BIOPSY; VERY ELDERLY; ADENOCARCINOMA; BONE TUMOR; BRAIN TUMOR; GENETICS; LUNG NEOPLASMS; MEDIASTINUM TUMOR; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOLOGY; PLEURA TUMOR; SECONDARY; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BRAIN NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; PLEURAL NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 84899070455     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000150     Document Type: Article

References (33)

1. Travis WD Brambilla E H.K. M-H et al. Pathology and Genetics of Tumours of the Lung Pleura Thymus and Heart. Lyon France: IARC Press; 2004.
2. Motoi N Szoke J Riely GJ et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes EGFR mutations and gene expression analysis. Am J Surg Pathol 2008;32:810-827.
3. Travis WD Brambilla E Noguchi M et al. International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-285.
4. Russell PA Wainer Z Wright GM Daniels M Conron M Williams RA. Does lung adenocarcinoma subtype predict patient survival A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 2011;6:1496-1504.
5. Warth A Muley T Meister M et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 2012;30:1438-1446.
6. Yoshizawa A Motoi N Riely GJ et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011;24:653-664.
7. Yoshizawa A Sumiyoshi S Sonobe M et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol 2013;8:52-61.
8. Woo T Okudela K Mitsui H et al. Prognostic value of the IASLC/ATS/ERS classification of lung adenocarcinoma in stage I disease of Japanese cases. Pathol Int 2012;62:785-791.
9. Sterlacci W Savic S Schmid T et al. Tissue-sparing application of the newly proposed IASLC/ATS/ERS classification of adenocarcinoma of the lung shows practical diagnostic and prognostic impact. Am J Clin Pathol 2012;137:946-956.
10. Yanagawa N Shiono S Abiko M Ogata SY Sato T Tamura G. New IASLC/ATS/ERS classification and invasive tumor size are predictive of disease recurrence in stage I lung adenocarcinoma. J Thorac Oncol 2013;8:612-618.
11. Gu J Lu C Guo J et al. Prognostic significance of the IASLC/ATS/ERS classification in Chinese patients-A single institution retrospective study of 292 lung adenocarcinoma. J Surg Oncol 2012;107:474-480.
12. Urer HN Kocaturk CI Gunluoglu MZ et al. Relationship between lung adenocarcinoma histological subtype and patient prognosis. Ann Thorac Cardiovasc Surg 2014;20:12-18.
13. Johnson DH Fehrenbacher L Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191.
14. Scagliotti GV Parikh P von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
15. Ceppi P Volante M Saviozzi S et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006;107:1589-1596.
16. Kerr KM. Clinical relevance of the new IASLC/ERS/ATS adenocarcinoma classification. J Clin Pathol 2013;66:832-838.
17. Heist RS Sequist LV Engelman JA. Genetic changes in squamous cell lung cancer: a review. J Thorac Oncol 2012;7:924-933.
18. Sørensen JB Hirsch FR Olsen J. The prognostic implication of histopathologic subtyping of pulmonary adenocarcinoma according to the classification of the World Health Organization. An analysis of 259 consecutive patients with advanced disease. Cancer 1988;62:361-367.
19. Sørensen JB Badsberg JH Olsen J. Prognostic factors in inoperable adenocarcinoma of the lung: a multivariate regression analysis of 259 patients. Cancer Res 1989;49:5748-5754.
20. Wu L Patten N Yamashiro CT Chui B. Extraction and amplification of DNA from formalin-fixed paraffin-embedded tissues. Appl Immunohistochem Mol Morphol 2002;10:269-274.
21. Do H Krypuy M Mitchell PL Fox SB Dobrovic A. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 2008;8:142.
22. Krypuy M Newnham GM Thomas DM Conron M Dobrovic A. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer 2006;6:295.
23. Do H Dobrovic A. Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil-DNA glycosylase. Oncotarget 2012;3:546-558.
24. Wu JY Yu CJ Chang YC Yang CH Shih JY Yang PC. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 2011;17:3812-3821.
25. Russell PA Barnett SA Walkiewicz M et al. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients. J Thorac Oncol 2013;8:461-468.
26. Sica G Yoshizawa A Sima CS et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol 2010;34:1155-1162.
27. Rekhtman N Ang DC Riely GJ Ladanyi M Moreira AL. KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. Mod Pathol 2013;26: 1307-1319.
28. Sun PL Seol H Lee HJ et al. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes EGFR/TTF-1 expressions and clinical features. J Thorac Oncol 2012;7:323-330.
29. Zhang Y Sun Y Pan Y et al. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res 2012;18:1947-1953.
30. Elston CW Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-410.
31. Epstein JI Allsbrook WC Jr. Amin MB Egevad LL; ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29:1228-1242.
32. Kao SC Pavlakis N Harvie R et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 2010;16:5805-5813.
33. Blayney JK Ceresoli GL Castagneto B et al. Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma. Eur J Cancer 2012;48:2983-2992.